Centessa Pharmaceuticals PLC
NASDAQ:CNTA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.73
18.67
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Centessa Pharmaceuticals PLC
Centessa Pharmaceuticals PLC
Total Liabilities & Equity
Centessa Pharmaceuticals PLC
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Liabilities & Equity
$360.2m
|
CAGR 3-Years
213%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Total Liabilities & Equity
£510.7m
|
CAGR 3-Years
69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Total Liabilities & Equity
$375.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Liabilities & Equity
$996.7m
|
CAGR 3-Years
52%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Liabilities & Equity
£597m
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Liabilities & Equity
£1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Centessa Pharmaceuticals PLC
Glance View
In the burgeoning landscape of biopharmaceutical innovation, Centessa Pharmaceuticals PLC stands out with a distinctive operating model that seeks to streamline the path from discovery to market. Centessa, founded in 2020, uniquely consolidates a range of biotech subsidiaries, each focused on distinct therapeutic areas. This structure enables them to maintain a sharp focus on scientific discovery while sharing corporate functions like operations, finance, and legal services to maximize efficiency. By integrating these companies under a single umbrella, Centessa hopes to mitigate the typical inefficiencies and bureaucratic delays that plague the path from pipeline to patient, driving forward their goal of developing transformative medicines. With an emphasis on nimblenes and productivity, Centessa monetizes its pipeline by advancing its most promising drug candidates through clinical development stages, subsequently seeking partnerships or acquisitions with larger pharmaceutical entities. The company's revenue stream hinges on the successful development and eventual commercialization or licensing of these pioneering therapies, often focusing on complex and challenging medical conditions. By nurturing a diverse portfolio of cutting-edge research programs — spanning areas like oncology, immunology, and rare diseases — Centessa strives to deliver breakthroughs that not only enhance patient lives but also provide substantial returns on investment through strategic collaborations and licensing deals within the pharmaceutical ecosystem.
See Also
What is Centessa Pharmaceuticals PLC's Total Liabilities & Equity?
Total Liabilities & Equity
360.2m
USD
Based on the financial report for Dec 31, 2023, Centessa Pharmaceuticals PLC's Total Liabilities & Equity amounts to 360.2m USD.
What is Centessa Pharmaceuticals PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
213%
Over the last year, the Total Liabilities & Equity growth was -19%. The average annual Total Liabilities & Equity growth rates for Centessa Pharmaceuticals PLC have been 213% over the past three years .
You don't have any saved screeners yet
